Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

Quest Diagnostics (DGX) carries a Zacks #3 (Hold) rank, alongside A grades for its Momentum Style Score and VGM Score. Shares rose 2.8% over the past four weeks; one analyst raised fiscal 2026 earnings estimates in the past 60 days, and the consensus estimate increased $0.02 to $11.17 per share. DGX's reported average earnings surprise is +6.2%.

Analysis

The signal here is more about momentum screening than a demonstrated change in Quest Diagnostics’ earnings power. A Hold rank alongside strong style scores is a mixed input: a small upward consensus revision driven by one analyst is not yet evidence of broad estimate support, and recent price strength can unwind quickly if revisions fail to broaden. Treat the “long-term” framing skeptically; the cited momentum measures are short-horizon indicators.

Over the next 1–3 months, the key read-through is whether Quest can convert testing demand and hospital outsourcing into sustained volume and favorable test mix without reimbursement pressure or labor, reagent, and collection costs eroding operating leverage. Labcorp is a relevant competitive comparator, but relative positioning should depend on reported volume, pricing, and margin trends—not this screening article. Over 6–18 months, greater hospital outsourcing could support reference-lab scale, while payer rate pressure, hospital insourcing, or weaker routine-testing demand could limit that benefit.

Contrarian view: a high momentum score may already reflect the easy part of the news, while the article offers little new fundamental evidence. There is no compelling standalone trade signal here. A falsifier for a constructive view would be weakening test volumes or margins, downward estimate revisions, or evidence that recent relative strength reverses; confirmation would require broader upward revisions and resilient operating metrics.

Key Decisions for Investors

• Do not chase DGX on this article alone; its promotional, factor-score framing does not establish a durable earnings catalyst.
• Keep DGX on a watchlist and reassess after the next earnings report: check test-volume trends, mix, reimbursement/pricing, operating margins, and the breadth of analyst estimate revisions.
• If considering a relative-value position against Labcorp, wait for comparable reported operating data; avoid assuming either company is gaining share from the other based on this article.
• Revisit a constructive stance if estimate revisions broaden and operating metrics confirm leverage; turn cautious if volumes or margins weaken or estimate revisions reverse.